Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPGS | Q05932 | 2/20 | 0.55 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | GART | P22102 | 5/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.38 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | ATIC | P31939 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222227 | 0.91 | FPGS (0.65) | FPGSSOSTNOS1NOS3NOS2 | |
| SCHEMBL2223139 | 0.89 | FPGS (0.54) | FPGSSOSTNOS1NOS3NOS2 | |
| SCHEMBL7856665 | 0.74 | FPGS (0.48) | FPGSSOSTNOS1NOS3NOS2 | |
| Tetrahydrofolate SCHEMBL28215829 | 0.72 | SOST (0.95) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL2691812 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL159231 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL30051444 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL9879710 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL29435894 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 | |
| Tetrahydrofolate SCHEMBL8030 | 0.70 | SOST (1.00) | FPGSSOSTGARTMTHFD2MTHFD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11219622-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200147072-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| US-10363250-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9549992-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160263237-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9192682-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | ENDOCYTE, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2349274-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | Endocyte, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2010033733-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | FPGS 8/4885SOST 2707/4885NOS1 4727/4885 |
| US-20200147072-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | FPGS 8/4885SOST 2707/4885NOS1 4727/4885 |
| US-20160263237-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | FPGS 8/4885SOST 2707/4885NOS1 4727/4885 |
| US-11219622-B2 | Folate receptor binding conjugates of antifolates | FOLR1, FOLR2, DHFR | FPGS 8/4885SOST 2707/4885NOS1 4727/4885 |
| US-10363250-B2 | Folate receptor binding conjugates of antifolates | FOLR1, FOLR2, DHFR | FPGS 25/4885SOST 920/4885NOS1 4758/4885 |
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | FPGS 25/4885SOST 920/4885NOS1 4758/4885 |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | FOLR1, FOLR2, DHFR | FPGS 8/4885SOST 2707/4885NOS1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.